Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial.

MLA

Friedlander, Michael, et al. “Patient-Centred Outcomes and Effect of Disease Progression on Health Status in Patients with Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation Receiving Maintenance Olaparib or Placebo (SOLO1): A Randomised, Phase 3 Trial.” The Lancet. Oncology, vol. 22, no. 5, May 2021, pp. 632–42. EBSCOhost, https://doi.org/10.1016/S1470-2045(21)00098-X.

APA

Friedlander, M., Moore, K. N., Colombo, N., Scambia, G., Kim, B.-G., Oaknin, A., Lisyanskaya, A., Sonke, G. S., Gourley, C., Banerjee, S., Oza, A., González-Martín, A., Aghajanian, C., Bradley, W. H., Liu, J., Mathews, C., Selle, F., Lortholary, A., Lowe, E. S., … DiSilvestro, P. (2021). Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial. The Lancet. Oncology, 22(5), 632–642. https://doi.org/10.1016/S1470-2045(21)00098-X

Chicago

Friedlander, Michael, Kathleen N Moore, Nicoletta Colombo, Giovanni Scambia, Byoung-Gie Kim, Ana Oaknin, Alla Lisyanskaya, et al. 2021. “Patient-Centred Outcomes and Effect of Disease Progression on Health Status in Patients with Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation Receiving Maintenance Olaparib or Placebo (SOLO1): A Randomised, Phase 3 Trial.” The Lancet. Oncology 22 (5): 632–42. doi:10.1016/S1470-2045(21)00098-X.